RCT: Effect of spironolactone on diastolic function and exercise capacity in diastolic heart failure (Aldo-DHF)

Source: JAMA Area: News Diastolic heart failure (heart failure with preserved ejection fraction) is a common condition affecting more than half of the total heart failure population but without established therapy. Furthermore, aldosterone stimulation may contribute to its progression.   The Aldo-DHF trial, a multicentre, prospective, randomised, double-blind, placebo-controlled trial, evaluated the effect of long-term spironolactone on diastolic function and exercise capacity in patients with diastolic heart failure.   The study randomised 422 ambulatory patients (mean age, 67 years; 52% female) with chronic New York Heart Association class II or III heart failure, preserved left ventricular ejection fraction of 50% or greater, and evidence of diastolic dysfunction to spironolactone (n=213; 25mg once daily) or matching placebo (n=209). The co-primary end points were changes in diastolic function on echocardiography and maximal exercise capacity (peak VO2) on cardiopulmonary exercise ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news